In AI drug discovery, Xaira made headlines this year, but they’re not the only game in town. At ENMEDIA, we’re keeping an eye on exciting companies with unique AI-driven drug discovery models. Catch them at BIO 2024.
Unlocking the therapeutic potential of RNA with AI and ML
Founding Year: 2014
Headquarters: New York, NY
Funding Status: Series A
Notable Achievements: Evisagenics’ SpliceCore® platform leverages RNA sequencing data and AI/ML algorithms to identify, test and validate drug targets with greater speed and precision than traditional methods. Envisagenics collaborates closely with biopharmaceutical companies and academic institutions, partnering with the Lung Cancer Initiative at Johnson & Johnson, Biogen, and BMS. The company will continue to scale its commercial offerings and advance its own pipeline, which includes immunotherapies for multiple indications in oncology and disease-modifying ASOs for neurodegenerative diseases.
Differentiator: Envisagenics’ technology harnesses the therapeutic potential of RNA splicing. Alternative RNA splicing holds the key to understanding and targeting over 370 diseases, including cancer and neurodegenerative disorders. SpliceCore boasts an impressive 400-fold increase in transcriptomic search space compared to conventional tools for target identification. Leveraging our extensive map of over 14 million RNA splicing events, SpliceCore enables the discovery of disease-specific targets, paving the way for the rational design and development of RNA therapeutics and immunotherapies.
Find Them at BIO 2024: Envisagenics’ Co-Founder and CEO, Dr. Martin Akerman, PhD, will be participating in the panel session “AI’s Trial by Fire: Experimental Validation in Drug Discovery” on Tuesday, June 4, 2024, at 11 AM PT.
Using AI for Every Step of Pharmaceutical Research and Development
Founding Year: 2014
Headquarters: Boston, MA and Hong Kong
Funding Status: Series D
Notable Achievements: Insilico Medicine uses advanced AI and machine learning for novel target discovery and generating molecular structures with specific properties. They utilize their proprietary platform technology, Pharma.AI, to expedite the development of life-saving medicines. The company has been featured in Fortune, GEN, CNBC and Nature and was named Fast Company’s Most Innovative Biotech Company in 2024.
Differentiator: Insilico has 31 internal programs and more than 40 companies use its Pharma.AI platform, making it the only generative AI-powered drug discovery and development platform offering end-to-end drug discovery and development services.
Find Them at BIO 2024: Dr. Petrina Kamya, President of Insilico Medicine Canada, will speak on Monday, June 3, 2024, at a panel titled “Use of AI in mRNA: The New Revolution?” Dr. Alex Zhavoronkov, Founder and CEO of Insilico Medicine, will speak on Tuesday, June 4, 2024, on a panel titled “AI’s Trial by Fire: Experimental Validation in Drug Discovery.” The company will be at Exhibition Booth 5657.